Walgreens Boots Alliance reported Q3 FY2024 net earnings of $344 million, a 190.8% increase from $118 million in the year-ago quarter. Operating income improved to $111 million from a loss of $477 million, driven by cost savings initiatives and improved U.S. Healthcare segment profitability. Sales grew 2.6% to $36.4 billion, with U.S. Retail Pharmacy sales up 2.3% to $28.5 billion.The company's U.S. Healthcare segment showed significant improvement, narrowing its operating loss to $220 million from $522 million year-over-year. International segment sales increased 2.8% to $5.7 billion, with Boots UK comparable retail sales growing 6.0%. The company maintained its pharmacy market leadership with 306.4 million prescriptions filled, up 0.5% from the previous year.Looking ahead, Walgreens faces challenges including a softer U.S. retail environment and increased reimbursement pressure. The company reduced its quarterly dividend by 48% to strengthen its balance sheet and announced plans to acquire prescription files for up to $375 million. Management continues to focus on cost management and strategic initiatives to improve operational efficiency.

Walgreens Boots Alliance reported Q3 FY2024 net earnings of $344 million, a 190.8% increase from $118 million in the year-ago quarter. Operating income improved to $111 million from a loss of $477 million, driven by cost savings initiatives and improved U.S. Healthcare segment profitability. Sales grew 2.6% to $36.4 billion, with U.S. Retail Pharmacy sales up 2.3% to $28.5 billion.The company's U.S. Healthcare segment showed significant improvement, narrowing its operating loss to $220 million from $522 million year-over-year. International segment sales increased 2.8% to $5.7 billion, with Boots UK comparable retail sales growing 6.0%. The company maintained its pharmacy market leadership with 306.4 million prescriptions filled, up 0.5% from the previous year.Looking ahead, Walgreens faces challenges including a softer U.S. retail environment and increased reimbursement pressure. The company reduced its quarterly dividend by 48% to strengthen its balance sheet and announced plans to acquire prescription files for up to $375 million. Management continues to focus on cost management and strategic initiatives to improve operational efficiency.